FreshPatents.com Logo
stats FreshPatents Stats
n/a views for this patent on FreshPatents.com
Updated: August 12 2014
newTOP 200 Companies filing patents this week


    Free Services  

  • MONITOR KEYWORDS
  • Enter keywords & we'll notify you when a new patent matches your request (weekly update).

  • ORGANIZER
  • Save & organize patents so you can view them later.

  • RSS rss
  • Create custom RSS feeds. Track keywords without receiving email.

  • ARCHIVE
  • View the last few months of your Keyword emails.

  • COMPANY DIRECTORY
  • Patents sorted by company.

Follow us on Twitter
twitter icon@FreshPatents

Use of tapentadol for inhibiting and/or treating depression and anxiety

last patentdownload pdfdownload imgimage previewnext patent


20120277319 patent thumbnailZoom

Use of tapentadol for inhibiting and/or treating depression and anxiety


The use of tapentadol (i) in the treatment of pain in a subject suffering from depression and/or from anxiety, and/or (ii) in the treatment or the inhibition of depression or anxiety.
Related Terms: Tapentadol

Browse recent Gruenenthal Gmbh patents - Aachen, DE
Inventors: Ilona STEIGERWALD, Ulrich Jahnel, Thomas Tzschentke
USPTO Applicaton #: #20120277319 - Class: 514654 (USPTO) - 11/01/12 - Class 514 
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) >Nitrogen Containing Other Than Solely As A Nitrogen In An Inorganic Ion Of An Addition Salt, A Nitro Or A Nitroso Doai >Benzene Ring Containing >Amino Nitrogen Attached To Aryl Ring Or Aryl Ring System By An Acyclic Carbon Or Acyclic Chain >The Chain Consists Of Two Or More Carbons Which Are Unsubtituted Or Have Acyclic Hydrocarbyl Substituents Only

view organizer monitor keywords


The Patent Description & Claims data below is from USPTO Patent Application 20120277319, Use of tapentadol for inhibiting and/or treating depression and anxiety.

last patentpdficondownload pdfimage previewnext patent

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority from co-pending U.S. provisional patent application No. 61/480,621, filed Apr. 29, 2011, the entire disclosure of which is incorporated herein by reference. Priority is also claimed based on European patent application no. EP 11 003 508.6, filed Apr. 29, 2011, the entire disclosure of which is likewise incorporated herein by reference.

BACKGROUND OF THE INVENTION

The present invention relates to the use of tapentadol in the (i) treatment of pain, preferably of neuropathic pain, more preferably of neuropathic pain due to lumbar radiculopathy, in a subject suffering from depression and/or from anxiety, and/or in the (ii) treatment or the inhibition of depression and/or of anxiety.

Tapentadol (CG5503), the chemical name for which is (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol, is a synthetic, centrally-acting analgesic that is effective for the treatment of moderate to moderately-severe acute or chronic pain. The compound can be employed as the free base or its physiologically acceptable salts and solvates. Preparation of the free base is known e.g. from U.S. Pat. No. 6,248,737 (=EP 693,475).

Tapentadol is a centrally acting analgesic with a dual mode of action consisting of μ-opioid receptor (MOR) agonism and norepinephrine (NE) reuptake inhibition. The efficacy, safety, and pharmacokinetic profile of tapentadol indicate that the drug is useful in treating acute as well as chronic pain.

Subjects suffering from pain often fall into depression and anxiety, especially if the pain is chronic or neuropathic. In patients with chronic or neuropathic pain 8 to 50% have been reported to have current major depression (Smith G R, The epidemiology and treatment of depression when it co-exists with somatoform disorders, somatization or pain. Gen Hosp Psychiatry 1992, 14: 265-276). In another analysis of 1,016 patients, the prevalence of depression was 12% in individuals with 3 or more pain complaints (Dworkin S F et al., Multiple pains and psychiatric disturbance: an epidemiological investigation. Arch Gen Psychiatry 1990, 47: 239-244).

The most serious consequences of major depression are suicide and increased rates of suicidal ideation and suicide completion have been reported by patients suffering from chronic pain conditions (Magni et al., Suicidality in chronic abdominal pain; an analysis of the Hispanic Health and Nutrition Examination Survey (HHANES). Pain 1998, 76: 137-144). Oncology patients with concomitant pain and depression were significantly more likely to request assistance in committing suicide as well as actively taking steps to commit suicide. In contrast those with pain in the absence of depression were unlikely to request the intervention of euthanasia and physician-assisted suicide (Emmanuel et al., Euthanasia and physician assisted suicide; attitudes and experiences of oncology patients, oncologists and the public. Lancet 1996, 347: 1810).

On the other hand, subjects suffering from depression and/or anxiety often have pain symptoms, which can be attributed to a somatoform disorder (psychogenic pain). The pain symptoms are physical symptoms, which typically do not have an identifiable physical origin. Instead, they are the result of internal psychological conflicts that are unconsciously expressed as physical signs.

It is evident that subjects suffering from depression and/or anxiety induced by pain or inducing pain symptoms are in need of medicaments for the treatment of both, the depression and/or anxiety as well as the pain.

US 2009/0215809 discloses pharmaceutical compositions comprising a crystalline prodrug of an antiepileptic drug, namely pregabalin ((S)-3-(Aminomethyl)-5-methylhexanoic acid) for the treatment of certain diseases and disorders, including, for example, neuropathic pain, generalized anxiety disorder, fibromyalgia, migraine, hot flashes, restless legs syndrome, and sleep disorders. The pharmaceutical composition may additionally comprise an opioid agonist selected from tramadol, tapentadol, and oxycodone as a second therapeutic agent.

Similarly, U.S. Pat. No. 7,868,043 discloses pharmaceutical compositions comprising a mesophasic pregabalin prodrug and methods of use thereof.

US 2010/0297181 discloses methods for treating epilepsy, mental disorders and/or deficits in sensory organ by administering to patients therapeutically effective amounts of AMPA receptor antagonists, i.e. antiepileptic drugs, in combination with one or more other active ingredients useful for treating epilepsy, mental disorders and/or deficits in the sensory organ. Tapentadol is mentioned in a list of suitable active ingredients to be administered in combination with AMPA receptor antagonists. As mental disorders, mood disorders, such as depressions, are listed.

The use of antiepileptic drugs, however, can be detrimental because it has been found that it can be associated with a significantly increased risk for suicide-related events in patients with depression (Arana et al., Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med 2010, 363: 542-551). Furthermore, a pharmaceutical composition comprising a combination of an antiepileptic and tapentadol can be disadvantageous because of adverse events caused by each drug itself and due to interactions of the drugs with each other, respectively.

Accordingly, there is a need for pharmaceutical compositions comprising a single pharmacologically active ingredient for use in the treatment of pain in a subject suffering from depression and/or anxiety, and/or for use in the treatment or the inhibition of depression and/or anxiety, wherein the single pharmacologically active ingredient may simultaneously or sequentially act as an antidepressant and as an analgesic.

US 2009/0306050 discloses compounds, such as lofepramine, exhibiting an activity as a potent norepinephrine (NE) reuptake inhibitor, and an activity at the dopamine D2 receptor sites. It was found that these special compounds are effective in the treatment and inhibition of various diseases and disorders associated with norepinephrine reuptake, such as pain predominant-type depression and depression secondary to chronic or neuropathic pain. However, antidepressants such as lofepramine exhibit several nuisance side effects and several warnings have been reported.

M. Afilalo et al., Clin. Drug Investig. 2010, 30(8), 489-505 discloses information concerning the efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee.

B. Kupferwasser et al., Osteoarthritis and Cartilage 2009, Vol. 17, Supplement 1, 179 discloses an evaluation of long-term treatment with tapentadol extended release and oxycodone controlled release in patients with chronic low back or osteoarthritis pain.

R. Lange et al., Osteoarthritis and Cartilage 2010, Vol. 18, Supplement 2, 147-148 discloses results from randomized, double-blind phase 3 studies of tapentadol prolonged release in patients with moderate to severe chronic nociceptive and neuropathic pain.

B. Kupferwasser et al., Osteoarthritis and Cartilage 2010, Vol. 18, Supplement 2, 149 discloses information concerning the health status of patients who received tapentadol prolonged release during an open-label extension study.

S. Schwartz et al., Current Medical Research & Opinion, 27(1), 2011, 151-162 discloses results of a randomized-withdrawal, placebo-controlled trial concerning safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy.

Accordingly, there remains a need for improved pharmaceutical compositions comprising a single pharmacologically active ingredient useful for treating pain and simultaneously or sequentially treating depression and/or anxiety.

SUMMARY

OF THE INVENTION

It is an object of the invention to provide medicaments for the treatment and inhibition of depression and/or of anxiety that have advantages compared to the medicaments of the prior art. This object has been achieved by the invention as described and claimed hereinafter.

While the analgesic efficacy of tapentadol is generally known, it has surprisingly been found that tapentadol is also effective in the treatment or inhibition of depression and/or of anxiety, preferably of depression and/or of anxiety that is induced by pain in a subject suffering from pain, and of depression and/or of anxiety inducing psychogenic pain.

In particular, in clinical trials concerning the efficacy of tapentadol against low back pain, depression (measured with HADS) was observed as undesired side effect. While in general, the occurrence of this symptom was at the borderline with respect to its clinical relevance, in the patient sub-population suffering from neuropathic pain, i.e. suffering from low back pain with a neuropathic component, a significant occurrence of depression was observed and tapentadol unexpectedly provided significant improvement.

In a first aspect, the invention is directed to the use of tapentadol in (i) the treatment of pain, preferably of neuropathic pain, more preferably of neuropathic pain due to lumbar radiculopathy, in a subject suffering from depression and/or from anxiety, and/or (ii) the treatment or inhibition of depression and/or of anxiety, with the proviso tapentadol is not administered in combination with an antiepileptic.

Thus, the invention relates to, inter alia, the use of tapentadol in a) the treatment of pain, preferably of neuropathic pain, more preferably of neuropathic pain due to lumbar radiculopathy, in a subject suffering from depression and/or from anxiety; b) the treatment of depression and/or of anxiety in a subject suffering from depression and/or from anxiety; c) the treatment of depression and/or of anxiety in a subject suffering from pain, preferably from neuropathic pain, more preferably from neuropathic pain due to lumbar radiculopathy; d) the inhibition of depression and/or of anxiety; e) the treatment of pain, preferably of neuropathic pain, more preferably of neuropathic pain due to lumbar radiculopathy, and the simultaneous treatment of depression and/or of anxiety; and/or f) the treatment of pain, preferably of neuropathic pain, more preferably of neuropathic pain due to lumbar radiculopathy, and simultaneous inhibition of depression and/or of anxiety.

A second aspect of the invention relates to a method for (i) the treatment of pain, preferably of neuropathic pain, more preferably of neuropathic pain due to lumbar radiculopathy, in a subject suffering from depression and/or from anxiety, and/or (ii) the treatment or the inhibition of depression and/or of anxiety, comprising the administration of an effective amount of tapentadol, with the proviso tapentadol is not administered in combination with an antiepileptic.

For the purpose of the specification, “tapentadol” is intended to include (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol, its physiologically acceptable salts and solvates thereof. Suitable physiologically acceptable salts include salts of inorganic acids, such as hydrochloric acid (tapentadol HCl), hydrobromic acid and sulfuric acid, and salts of organic acids, such as methane sulfonic acid, fumaric acid, maleic acid, acetic acid, oxalic acid, succinic acid, malic acid, tartaric acid, mandelic acid, lactic acid, citric acid, glutamic acid, acetylsalicylic acid, nicotinic acid, aminobenoic acid, □-liponic acid, hippuric acid and asparaginic acid. The preferred salt is the hydrochloride salt.

For the purpose of the specification, unless expressly stated otherwise, doses of tapentadol relate to the free base. Thus, when a physiologically acceptable salt of tapentadol is used instead, its dose has to be adapted to the equivalent dose of the free base. For example, a dose of “200 mg” means an amount of 200 mg of the free base or any equivalent amount of a physiologically acceptable salt or solvate corresponding to 200 mg of the free base (e.g. about 233 mg of the hydrochloride). If not expressly stated otherwise, doses are “per administration”, not “per day”.

The term “depression” is known to persons skilled in the art. Depression is a common mental disorder that presents with depressed mood, loss of interest or pleasure, feelings of guilt or low self-worth, disturbed sleep or appetite, low energy, and poor concentration. These problems can become chronic or recurrent and lead to substantial impairments in an individual\'s ability to take care of his or her everyday responsibilities. At its worst, depression can lead to suicide. Depression occurs in persons of all genders, ages, and backgrounds. In this regard it can further be referred e.g. to the International Classification of Diseases (ICD-10), particularly to its Chapter V. As used in the specification, the term “depression” preferably covers hereditary depressions and depressions, which represent a reaction of stressors in the environment, or both. Preferably, pain is regarded as stressor in the environment. Furthermore, the term “depression” also covers depressive disorders, such as mood disorder, major depressive disorder, and dysthymic disorder. Preferably, the term “depression” also relates to depression induced by pain, i.e. depression that arises from pain in a subject suffering from pain. The depression is typically caused by the chronic nature of the pain.



Download full PDF for full patent description/claims.

Advertise on FreshPatents.com - Rates & Info


You can also Monitor Keywords and Search for tracking patents relating to this Use of tapentadol for inhibiting and/or treating depression and anxiety patent application.
###
monitor keywords



Keyword Monitor How KEYWORD MONITOR works... a FREE service from FreshPatents
1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored.
3. Each week you receive an email with patent applications related to your keywords.  
Start now! - Receive info on patent apps like Use of tapentadol for inhibiting and/or treating depression and anxiety or other areas of interest.
###


Previous Patent Application:
Non-steroidal anti-inflammatory drugs for cough
Next Patent Application:
Inhibition of the survival of skin cancer by cyclohexenone compounds from antrodia camphorata
Industry Class:
Drug, bio-affecting and body treating compositions
Thank you for viewing the Use of tapentadol for inhibiting and/or treating depression and anxiety patent info.
- - - Apple patents, Boeing patents, Google patents, IBM patents, Jabil patents, Coca Cola patents, Motorola patents

Results in 0.79276 seconds


Other interesting Freshpatents.com categories:
Computers:  Graphics I/O Processors Dyn. Storage Static Storage Printers

###

Data source: patent applications published in the public domain by the United States Patent and Trademark Office (USPTO). Information published here is for research/educational purposes only. FreshPatents is not affiliated with the USPTO, assignee companies, inventors, law firms or other assignees. Patent applications, documents and images may contain trademarks of the respective companies/authors. FreshPatents is not responsible for the accuracy, validity or otherwise contents of these public document patent application filings. When possible a complete PDF is provided, however, in some cases the presented document/images is an abstract or sampling of the full patent application for display purposes. FreshPatents.com Terms/Support
-g2-0.2548
     SHARE
  
           

FreshNews promo


stats Patent Info
Application #
US 20120277319 A1
Publish Date
11/01/2012
Document #
13458510
File Date
04/27/2012
USPTO Class
514654
Other USPTO Classes
International Class
/
Drawings
0


Tapentadol


Follow us on Twitter
twitter icon@FreshPatents